To Pfizer. Arvinas shall have the right, during normal business hours and upon reasonable notice, to inspect and copy all such records of Pfizer referred to in Section 2.6.1 solely to the extent related to Arvinas Technology Improvements or Joint Information and Inventions, as reasonably appropriate in the exercise of the rights granted hereunder with respect to Arvinas Technology Improvements and Joint Information and Inventions. Arvinas shall maintain such inspected records and the information disclosed therein in confidence in accordance with Article 4. Upon reasonable request, Pfizer shall provide copies of the records described in Section 2.6.1, as are related to Arvinas Technology Improvements or Joint Information and Inventions, to Arvinas.
To Pfizer. Without limiting any other license or sublicense granted under this Agreement or the Commercialization Agreement and subject to the terms and conditions of this Agreement, BioNTech on behalf of itself and its Affiliates, effective as of the Effective Date, hereby grants (and will procure that its Affiliates grant) to Pfizer a non-exclusive, royalty-free, fully paid-up, sublicensable license under all BioNTech Improvements and Product Technology that were solely or jointly made or invented by Pfizer Representatives to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize, have Commercialized and otherwise Exploit any products or processes outside the Field. In addition to the obligations set forth in Section 3.10 for the avoidance of doubt, the license granted in this Section 3.5.1 shall not include or imply a right of Pfizer to use any of BioNTech’s Confidential Information (that is not a BioNTech Improvement or Product Technology) outside the Field.
To Pfizer. Subject to the terms and conditions of this Agreement, for the Term BioNTech hereby grants to Pfizer and its Affiliates (i) a non-exclusive, royalty-free license to use the BioNTech House Marks in the Pfizer Commercialization Territory solely as set forth in Section 9.12 and (ii) an exclusive (even as to BioNTech), royalty-free, fully paid-up, non-assignable and sublicensable license to use the Product Trademarks in the Pfizer Commercialization Territory, in each case, solely in connection with the exercise by Pfizer or its Affiliates of Pfizer’s rights or obligations under this Agreement or the performance by Pfizer or its Affiliates of Pfizer’s Commercialization Activities.
To Pfizer. Subject to the terms and conditions of this Agreement, Wave hereby grants to Pfizer a nonexclusive, [***] license [***], including the right to grant sublicenses solely to Affiliates and to contractors performing work for Pfizer under the Research Plan, to use Wave’s Confidential Information, Wave Patent Rights and Wave Know-How [***].
To Pfizer. Subject to the terms and conditions of this Agreement, Licensee hereby grants to Pfizer a non-exclusive, sublicensable, royalty-free license under the Licensee Developed IP to [***] within the Territory. To the extent that any of the Licensee Developed IP is Controlled by an Affiliate of Licensee, then Licensee shall cause such Affiliate to take all necessary actions to give effect to the license granted under this Section 2.1.2.
To Pfizer. Subject to the terms and conditions of this Agreement, including the Options in Section 2.4, Codex hereby grants to Pfizer a non-exclusive, royalty-free, fully paid-up license (and, to the extent any Codex Technology is Controlled by Codex pursuant to a Codex Third Party Agreement, a sublicense, as applicable), with no right to sublicense other than to Affiliates of Pfizer or Third Party subcontractors under the Codex Technology solely to the extent necessary to perform Pfizer’s activities under the Research Plan. 2.1.2.
